LMS PhD in Cancer Imaging: Tracking Drug Response with 4D OPM and OCT

LMS PhD in Cancer Imaging: Tracking Drug Response with 4D OPM and OCT

Research Question and Project Fit

How do a cancer cell's state and history shape its response to a drug, and can that response be followed in a three-dimensional model over time? This project links optical hardware, image-analysis software and quantitative cancer biology. Four-dimensional imaging means three spatial dimensions followed through time; it can reveal trajectories that a single endpoint misses. The LMS listing names Alexis Barr, Christopher Dunsby and Susana Ros. Its project description proposes OPM hardware/software development and label-free OCT on dOPM. LMS recruitment page, official project DOCX.

Relevant preparation connects physics, optical engineering or biomedical imaging with quantitative cancer biology. The student is expected to make imaging hardware/software contributions and use them to study how cell state and history shape heterogeneous drug response in three-dimensional tumour models.

Research Work and Feasibility

The advertised work has two connected imaging tasks: improve the OPM hardware and analysis software to follow cell-state responses in three-dimensional cancer spheroids, and develop label-free OCT on the dOPM system to track cells between fluorescence acquisitions with a lower light dose. OPM is an existing platform; OCT integration remains proposed doctoral work. The project also aims to understand how identified drug combinations affect cell-cycle responses and, later, the mechanisms and timing of synergy. No particular combination or clinical benefit is established by the advertisement.

The key research distinction is between observing a change and explaining it. The same drug response can reflect cell state, prior history or the local environment. A feasible thesis must connect reliable optical measurements and tracking to a bounded biological question, with a clear balance between hardware development and cancer-biology interpretation. The actual models, available data, assigned resources and first-year milestones require agreement with the team.

University, Discipline and Training

The LMS transdisciplinary route explicitly brings physical-sciences, mathematics and engineering backgrounds into biomedical research. Training here would connect Barr's cell-cycle research with Dunsby's optical methods; the individual allocation of instrument, analysis and biological work still needs agreement. LMS PhD students are enrolled through Imperial College London's Faculty of Medicine and access Imperial Graduate School training. The concrete training context is Imperial registration, Graduate School support and the complementary research groups. Individual courses, progress reviews, meeting frequency and allocated resources still need confirmation. Sources: LMS studentships overview, Imperial league tables, THE Imperial profile.

The LMS four-year studentship states a stipend of £26,500 per year, full tuition fees, research consumables and overseas visa costs for successful award holders; it is open to applicants of all nationalities. The 2026–27 application form sets the deadline at 09:00 UK time (Europe/London) on 18 November 2026. The planned start is 4 October 2027, subject to individual registration arrangements. Current application status is unconfirmed. The reference-arrival deadline, individual selection and AstraZeneca-linked IP or publication terms still need confirmation. Source: LMS recruitment page.

Supervisor and lab assessment

Alexis Barr is officially Head of the Cell Cycle Control group at LMS. Her profile and group page align tightly with the cancer biology side of the project: quantitative single-cell imaging, mathematical modelling, perturbation screens, cell-cycle entry/exit, quiescence and cancer proliferation. The Barr Lab page also emphasises live single-cell imaging with fluorescent biosensors and signalling proteins. Sources: Alexis Barr profile, Cell Cycle Control group, Barr Lab.

Christopher Dunsby supplies the optical physics foundation. Imperial identifies him as Professor of Biomedical Optics in the Department of Physics. Imperial’s OPM material describes OPM as a single-objective light-sheet method, and a 2026 Imperial news article says Dunsby invented OPM and that his lab has applied it to cancer spheroids and organoids. This is unusually direct alignment between a co-supervisor's technical track record and the proposed instrument platform. Sources: Imperial Physics people page, Imperial OPM page, Imperial OPM commercialisation news.

Susana Ros is named in the official project DOCX as the AstraZeneca supervisor. The DOCX verifies the industry link, but the publicly accessible evidence base here is thinner than for Barr and Dunsby. Applicants should ask what Ros's supervisory role will be, whether the project includes an AstraZeneca placement, and how confidential compounds, data and publication approvals will be handled.

Recent publications and research quality

Cell state and long-term drug response

The 2024 British Journal of Cancer p21 study in non-small cell lung cancer supports the premise that cell state and history can shape drug response. It provides biological context, without establishing that this proposed three-dimensional imaging project has identified an effective combination. p21 NSCLC record.

Growth, stress and longer-term responses

The 2023 Molecular Cell study concerns CDK4/6 inhibitor-mediated cell overgrowth, osmotic stress, replication stress and senescence. Its relevance is the interpretation of longer-term cell responses; it does not establish the proposed OPM/OCT integration. The group also lists 2024 image-screening and cell-cycle-latch work. The available summaries do not establish complete author contributions or methods beyond the details reported. Molecular Cell record, group publications.

Established OPM and proposed OCT integration

The imaging evidence has a different scope. Dunsby’s 2008 OPM paper is foundational, while the 2025 PNAS Nexus dOPM paper supports the official project statement that high-content 3D imaging of many spheroids over days is feasible. The OCT part is less directly supported by a recent Dunsby-specific paper in the cited material, so OCT-on-dOPM should be treated as a development aim rather than a fully established platform. Sources: Dunsby OPM PubMed, dOPM 2025 Imperial repository, full-field OCT review.

Research direction and field outlook

The project is timely because cancer-drug response is often heterogeneous, dynamic and microenvironment-dependent. Moving from 2D monolayers to 3D spheroids can make the model more realistic, while long-term low-phototoxic 4D imaging can capture trajectories rather than only endpoints. Combining fluorescence reporters with label-free OCT is a plausible way to reduce light dose between fluorescence acquisitions.

The main intellectual challenge is integration. A student must connect optical design, image analysis, cell tracking, drug perturbation, spheroid biology and mechanistic interpretation. If the project becomes too hardware-heavy, biological conclusions may remain shallow; if it becomes too biology-heavy, the optical contribution may become routine service work. The applicant should ask for a clear first-year success criterion and how the thesis will balance instrument development against cancer-drug-response discovery.

Funding, cost and living feasibility

The advertised LMS package provides £26,500 tax-free each year for four years, tuition fees, consumables and overseas visa costs for successful award holders. London living costs remain the main financial risk, especially rent, deposits and travel. The project information does not establish a complete personal London budget. Obtain actual housing and arrival costs, then clarify payment timing and whether conferences, industry visits, computing and image-data storage are included. Visa-cost coverage does not itself confirm IHS or dependant costs. Sources: LMS recruitment page, Imperial living costs.

Chinese/international eligibility and application fit

The official LMS page says applicants of all nationalities are eligible. Academic criteria include a first or upper-second-class honours degree or equivalent in a relevant scientific subject; a Master's is preferred, and at least one year of equivalent research experience may be considered. Imperial English and doctoral communication requirements still apply. A Chinese qualification must be assessed individually against the required academic entry standard and Imperial English requirements. A preferred Master's or consideration of equivalent research experience should not be presented as removing the underlying degree requirement. No particular English-test score or automatic exemption is established in these saved project reports. Sources: LMS recruitment page, Imperial international qualifications guidance, Imperial English requirements.

Best-fit evidence would include optics, microscopy, photonics, biomedical engineering, image processing, Python/Matlab, quantitative analysis, instrumentation, cell-culture exposure, or cancer-biology collaboration. A pure biology applicant would need unusually strong quantitative/imaging evidence; a pure physics applicant should show credible motivation to work with live cancer spheroids, fluorescent reporters and biological variability.

Career and market implications

The work can develop skills relevant to academic biomedical imaging, microscopy instrumentation, image-analysis/data-science roles, pharma imaging biomarkers, cancer research and biotech platform development. UK Government life-sciences evidence shows life sciences remains a strategic sector with skilled-labour demand, while CRUK and Imperial/LMS evidence support a UK cancer-research training ecosystem. Industry collaboration with AstraZeneca could be valuable if the project includes real supervision, data exposure or secondment, but it should not be overclaimed until confirmed. Sources: UK life sciences indicators, UK Life Sciences Jobs Plan, CRUK PhD career opportunities.

Application and Questions to Resolve

Email the completed official form to students@lms.mrc.ac.uk, provide two academic referees' contact details and ask them to send references directly. Registering interest is not an application. The cutoff is 09:00 UK time (Europe/London) on 18 November 2026; whether references share it still needs LMS confirmation. Current application status is unconfirmed. Planned entry is 4 October 2027, subject to individual admission and funding.

Research and practical questions

1. The official application form specifies 18 November 2026, 9am UK time; confirm whether references share the same cutoff.
2. Ask what portion of the PhD is expected to be OPM hardware, OCT development, software pipelines, spheroid biology and drug-mechanism work.
3. Confirm which cancer cell models, reporters and drug combinations are already available.
4. Ask what is already functional on the dOPM system and what the student must develop from scratch for OCT.
5. Confirm AstraZeneca's supervisory role, potential placement, IP rules, publication review and compound/data access.
6. Ask whether ATAS, export-control or industry confidentiality checks apply for a Chinese applicant.

Evidence and source list

Current application status is unconfirmed; the stated deadline and planned entry date do not show that recruitment is still open. The cited papers serve different evidential roles: the 2008 OPM paper is foundational, the 2025 dOPM study supports multi-spheroid 3D imaging, and the OCT citation is a review. These sources do not establish that OCT has already been integrated on dOPM. The available publication summaries also do not establish complete individual author contributions or supplementary-method details.

Key sources used include the official LMS recruitment page, official Barr/Dunsby project DOCX, Alexis Barr profile, Cell Cycle Control group page, Imperial Physics people page, Imperial OPM page, Imperial OPM commercialisation news, p21 NSCLC paper, CDK4/6 Molecular Cell paper and dOPM 2025 paper.

• Current LMS 2026–27 application form: 9am UK time.